Catalog No.
Product Name
Application
Product Information
Citations
-
GA mitochondrial matrix inhibitor
Gamitrinib TPP is a GA mitochondrial matrix inhibitor. Gamitrinib TPP is offered as the hexafluorophosphate salt.
-
Hsp90 inhibitor
IPI-504 is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90). - Geranylgeranylacetone can induce expression of HSP70, HSPB8, and HSPB1.
-
Hsp70 inducer
TRC051384 hydrochloride is an inducer of heat shock protein Hsp70.
-
HSP90 inhibitor
Macbecin I is an ansamycin antibiotic compound that inhibits Hsp90 activity with IC50 value of μM by binding to the ATP-binding site. -
HSP70 inducer
TRC 051384, belonging to substituted 2-propen-1-one class, is a potent inducer of heat shock protein 70 (HSP70) [1]. Induction of HSP70 is a natural response of stressed cells that protects neuronal cells from a variety of insults including acute ischemia. -
Antioxidant
Ethoxyquin is an antioxidant that is widely used in animal feed to protect against lipid peroxidation and fat rancidity in chicken, salmon, and beef. -
MAPKAPK2(MK2) inhibitor
MK2-IN-1 hydrochloride is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode. -
HSP inhibitor
HSP70-IN-1 is a heat shock protein (HSP) inhibitor; inhibits the growth of Kasumi-1 cells with an IC50 of 2.3 μM. -
co-inducer of heat shock proteins (HSP)
Arimoclomol maleate (BRX-220) is a co-inducer of heat shock proteins (HSP). -
Hsc70 and Hsp70 inhibitor
Apoptozole (Apoptosis Activator VII) is an inhibitor of the ATPase domain of Hsc70 and Hsp70, with Kds of 0.21 and 0.14?μM, respectively, and can induce apoptosis. -
Hsp90 inhibitor
SNX-5422 Mesylate (PF-04929113 Mesylate), a prodrug of SNX-2112, is an orally active Hsp90 inhibitor, with a Kd of 41 nM, and also induces Her-2 degradation, with an IC50 of 37?nM. -
Hsp90-Cdc37 interaction disruptors
Hsp90-Cdc37-IN-1 is an Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance, with an IC50 of 140 nM. -
cell motility and cell invasion inhibitor
KBU2046 is an oral, highly selective inhibitor of cell motility and cell invasion in vitro. KBU2046 binds chaperone heterocomplexes, selectively alters binding of client proteins that regulate motility, and lacks all of the hallmarks of classical HSP90 inhibitors. KBU2046 inhibits cancer metastasis and prolongs life. -
Hsp90 inhibitor
Alvespimycin is a selective Hsp90 inhibitor with a GI50 of 53 nM. -
Hsp90 inhibitor
Retaspimycin is a potent and water-soluble inhibitor of Hsp90, with EC50s of 119 nM for both Hsp90 and Grp9. -
HSP90β Inhibitor
CCT018159 is an ATP-competitive inhibitor of the HSP90β protein, exhibiting an IC50 of 3.2 μM against human HSP90β ATPase and 6.6 μM against yeast HSP90β ATPase. This compound induces cell cycle arrest and apoptosis in various tumor cell lines while effectively inhibiting processes such as invasion and angiogenesis. CCT018159 is particularly valuable for research applications in cancer biology and therapeutic development. -
HSP90AA1 Interactor, CNR1 Interactor, DRD2 Interactor,
Terrestrosin D is a small molecule that interacts with HSP90AA1, CNR1, and DRD2, functioning as an orally active apoptosis inducer. It effectively induces cell cycle arrest at the G1 and S phases while diminishing mitochondrial membrane potential, leading to the inhibition of growth in both cancer and endothelial cells. This compound is under investigation for its potential therapeutic applications in castration-resistant prostate cancer and pulmonary fibrosis. -
HSP Inhibitor
Cucurbitacin D is a potent HSP90 inhibitor that disrupts the interaction between Hsp90 and co-chaperones Cdc37 and p23. This compound exhibits significant biological activities, including the induction of cell cycle arrest and apoptosis, showcasing its potential as an anti-tumor and anti-inflammatory agent. Cucurbitacin D is useful in research applications aimed at understanding the role of heat shock proteins in cancer and inflammation. -
Hsp70 Inhibitor
JG-231 is an allosteric inhibitor targeting heat shock protein 70 (Hsp70). By disrupting the interaction between Hsp70 and BAG family proteins, JG-231 exhibits an inhibition constant (Ki) of 0.11 μM. This compound effectively inhibits tumor cell proliferation and induces apoptosis, demonstrating significant antitumor activity. JG-231 is valuable for research into the roles of Hsp70 in cancer biology and its potential as a therapeutic target. -
HSP90 C-terminal Inhibitor
NCT-58 is a potent C-terminal inhibitor of HSP90, which effectively disrupts the chaperone’s function without inducing the heat shock response. This compound exhibits significant anti-tumor activity by simultaneously downregulating HER family members and inhibiting Akt phosphorylation. Additionally, NCT-58 demonstrates the capability to kill trastuzumab-resistant breast cancer stem-like cells and induces apoptosis in HER2-positive breast cancer cells, making it a valuable tool for research on cancer therapeutics and resistance mechanisms. -
Hsp70 Inhibitor
YK5 is a potent and selective inhibitor of the heat shock protein 70 (Hsp70). It demonstrates a strong affinity for cytosolic Hsp70s in cancer cells, disrupting the formation of active oncogenic Hsp70/Hsp90/client protein complexes. This biological activity makes YK5 a valuable tool for research applications focused on cancer biology and the study of protein homeostasis in oncogenic processes. -
HSP Synthesis Inhibitor
KNK423 is a specific inhibitor of heat shock protein (HSP) synthesis, targeting HSP70. This compound enhances the efficacy of Amphotericin B against resistant strains of Aspergillus terreus by disrupting HSP expression. KNK423 is valuable for research in cancer therapy and bacterial infection mechanisms. -
FKBP51-Hsp90 Interaction Inhibitor
FKBP51-Hsp90-IN-1 is a selective inhibitor targeting the FKBP51-Hsp90 protein-protein interaction, exhibiting an IC50 value of 0.1 μM against FKBP51. This compound is valuable for research into stress-related diseases, Alzheimer's disease, and various metabolic disorders, owing to its ability to modulate protein interactions critical for cellular stress responses and stability. Its specificity makes it a potent tool for elucidating the role of FKBP51 in disease mechanisms. -
HSP90 Inhibitor
HSP90-IN-20 is a potent inhibitor of Heat Shock Protein 90 (HSP90) with an IC50 of ≤10 μM. This compound plays a significant role in cancer research by impeding the function of HSP90, which is critical for the stability and activity of several oncogenic proteins. HSP90-IN-20 can be utilized to investigate the therapeutic potential of HSP90 inhibition in various cancer models. -
Hsp70-targeting Peptide
A17 peptide is an Hsp70-targeting peptide that binds to the ATP-binding domains of Hsp70, specifically inhibiting its chaperone activity. This inhibition enhances the sensitivity of cancer cells to apoptosis induced by chemotherapeutic agents, including Cisplatin. A17 peptide is valuable in anticancer chemotherapy research, particularly in studies related to multiple myeloma and other malignancies. -
HSP70/DnaK Substrate Peptide
HSP70/DnaK substrate peptide is a specific peptide recognized and bound by the HSP70/DnaK molecular chaperone. This substrate peptide is essential for probing the functional mechanisms of HSP70/DnaK, facilitating the investigation of its role in protein folding, stabilization, and stress response pathways. It serves as a valuable tool for research applications focused on understanding molecular chaperone activity and cellular proteostasis. -
HSP90 Inhibitor
Hsp90-IN-17 is a selective inhibitor of Heat Shock Protein 90 (HSP90) that interferes with its chaperone activity. This compound demonstrates significant potential in addressing various proliferative conditions, including cancer and neurodegenerative disorders. Hsp90-IN-17 serves as a valuable tool for research focused on the molecular mechanisms of HSP90 and its role in disease progression and treatment responses. -
HSP90 Inhibitor
Aminohexylgeldanamycin hydrochloride is a potent inhibitor of Heat Shock Protein 90 (HSP90). This Geldanamycin derivative demonstrates significant antiangiogenic and antitumor activities, making it valuable for cancer research. Its ability to modulate HSP90 function provides insights into the molecular mechanisms of tumorigenesis and offers potential therapeutic applications in oncology. -
SIRT2/Hsp70 Inhibitor
YM-08 is a selective inhibitor of SIRT2 and Hsp70, exhibiting an IC50 of 19.9 μM for SIRT2. This compound effectively penetrates the blood-brain barrier, making it a valuable tool for studying neurodegenerative diseases and cellular stress responses. Its dual inhibitory activity allows for investigation into SIRT2 and Hsp70's roles in various biological processes and potential therapeutic applications. -
HSP70 Inhibitor
DMT003096 is a selective inhibitor of HSP70, a heat shock protein that plays a critical role in cellular stress responses. Its upregulation has been associated with various cancers, including breast, lung, colon, and cervical cancer. This compound is valuable for research applications targeting cancer therapies and investigating the role of HSP70 in tumor progression and survival mechanisms. -
Hsp90 Inhibitor
Hsp90-IN-40 is a specific inhibitor targeting the C-terminal domain of heat shock protein 90 (Hsp90). It demonstrates significant antiproliferative activity against breast cancer cell lines SKBr3 and MCF-7, with IC50 values of 2.57 µM and 2.43 µM, respectively. By disrupting the function of Hsp90, Hsp90-IN-40 promotes the degradation of Hsp90-dependent proteins, thereby inhibiting cancer cell growth. This compound is valuable for research applications focusing on breast cancer therapeutics and mechanisms of Hsp90 inhibition. -
HSP90 Inhibitor
STA-1474 is a potent and selective inhibitor of Heat Shock Protein 90 (HSP90), primarily functioning by disrupting its chaperone activities, which are crucial for the stability and function of numerous oncogenic proteins. This compound induces apoptosis in tumor cells and exhibits significant antitumor efficacy in spontaneous canine cancer models, such as osteosarcoma and thyroid carcinoma. STA-1474 is valuable for research on solid tumors, including osteosarcoma and breast cancer, and offers insights into the role of HSP90 in cancer biology.
